Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2017-07-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2017.7115PMID 28672316PMCID PMC5817477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comment on American Diabetes Association. Standards of Medical Care in Diabetes—2017. Diabetes Care 2017;40(Suppl. 1):S1–S135

  2017cited by this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

  2017cited by this paper
• A taxonomy of estimands for regulatory clinical trials with discontinuations

  2016cited by this paper
• Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global HAT study

  2016cited by this paper
• Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.

  2016cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2014cited by this paper
• Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.

  2014cited by this paper
• Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications

  2014cited by this paper
• Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012)

  2014cited by this paper
• Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk

  2014cited by this paper
• Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

  2013cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2013cited by this paper
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview

  2013cited by this paper
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013cited by this paper
• Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial

  2013cited by this paper
• Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

  2013cited by this paper
• Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia

  2012cited by this paper
• Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

  2012cited by this paper
• The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

  2010cited by this paper
• Severe hypoglycemia and risks of vascular events and death.

  2010cited by this paper
• Long‐acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta‐analysis

  2009cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2006cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

  2005cited by this paper
• Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

  2005cited by this paper
• Assessment of the Impact of Fear of Hypoglycemic Episodes on Glycemic and Hypoglycemia Management

  2005cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

  2001cited by this paper
• Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.

  2000cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

  2000cited by this paper
• A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

  2000cited by this paper
• Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial

  2000cited by this paper
• Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

  2000cited by this paper
• Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.

  1999cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Uniform Requirements for Manuscripts Submitted to Biomedical Journals

  1991cited by this paper
• Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.

  1987cited by this paper

• A Boundary Reshaped Biosensor with an Axon‐Like Microstructure for Diabetes Care Monitoring

  2026cites this paper
• How new diabetes technology will improve outcomes after total pancreatectomy?

  2026cites this paper
• Type 1 Diabetes: A Review.

  2026cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.

  2025cites this paper
• NEW FORMS AND TECHNOLOGIES OF INSULIN THERAPY IN TYPE 1 DIABETES - A SYSTEMATIC LITERATURE REVIEW

  2025cites this paper
• Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis

  2025cites this paper
• Advancing Type 1 Diabetes Management: Integrating Novel Therapies, Technologies, and Adjunctive Approaches.

  2025cites this paper
• How to improve the quality of euglycemic glucose clamp tests in long-acting insulin studies

  2025cites this paper
• Trends in baseline HbA1c and body-mass index in randomised trials of people with type 1 diabetes from 1993 to 2025: an IMI2 SOPHIA systematic review and meta-analysis

  2025cites this paper
• The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes

  2025cites this paper
• 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association

  2025cites this paper
• Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial

  2025cites this paper
• Basal insulin analogues in type 1 diabetes – Does one size fit all? Lessons from the HypoDeg trial based on single-patient outcomes

  2024cites this paper
• Objetivos del tratamiento de la diabetes mellitus tipo 1

  2024cites this paper
• Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross‐sectional study

  2024cites this paper
• Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes

  2024cites this paper
• 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association

  2024cites this paper
• New advances in type 1 diabetes

  2024cites this paper
• Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review

  2024influential citation
• Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study

  2024influential citation
• Bridging dose of U‐100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice‐daily glargine users

  2024cites this paper
• Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications

  2024cites this paper
• Dual-Functional Fluorescent Probe in the Diagnosis of Liver Injury and the Evaluation of Drug Therapy with Double Signal Amplification

  2024cites this paper
• Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins

  2024cites this paper
• Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)

  2024cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.

  2024cites this paper
• Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.

  2024cites this paper
• Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial

  2023cites this paper
• The effect of insulin analogs in people with type 1 diabetes at increased risk of severe hypoglycemia

  2023influential citation
• Nighttime hypoglycemia in Japanese children with type 1 diabetes mellitus treated with multiple daily injection insulin therapy.

  2023cites this paper
• Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)

  2023cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.

  2023cites this paper
• Insulin biobetters and biosimilars in clinical practice

  2023cites this paper
• [New Insulins for Type 1 Diabetes treatment].

  2023cites this paper
• The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia

  2023cites this paper
• Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences.

  2023cites this paper
• Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades

  2023influential citation
• Signaling pathway of targeting the pancreas in the treatment of diabetes under the precision medicine big data evaluation system

  2023cites this paper
• Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia

  2023cites this paper
• No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study

  2023cites this paper
• The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range

  2023cites this paper
• Hypoglycemia in Adults.

  2023cites this paper
• Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes

  2022cites this paper
• Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Diabetes mellitus: what the neurologists need to know

  2022cites this paper
• Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison

  2022cites this paper
• The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults

  2022cites this paper
• Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia

  2022influential citation
• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

  2022cites this paper
• Diurnal Variation of Real-Life Insulin Sensitivity Factor Among Children and Adolescents With Type 1 Diabetes Using Ultra-Long-Acting Basal Insulin Analogs

  2022cites this paper
• Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons

  2022cites this paper
• The Cost-Effectiveness Of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.

  2022cites this paper
• One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

  2022cites this paper
• Pregnancy outcomes in women with type 1 diabetes using insulin degludec

  2022cites this paper
• Scientific advisory on nocturnal hypoglycemia in insulin-treated patients with diabetes: Recommendations from Indian experts.

  2022cites this paper
• Tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano»

  2022cites this paper
• The 2021–2022 position of Brazilian Diabetes Society on insulin therapy in type 1 diabetes: an evidence-based guideline to clinical practice

  2022influential citation
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

  2022cites this paper
• Series: Cardiovascular outcome trials for diabetes drugs.

  2022cites this paper
• Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

  2022cites this paper
• Hypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies

  2022cites this paper
• Comparison of Once-daily versus Twice-daily Injection of Insulin Detemir in Children with Type 1 Diabetes Mellitus

  2022cites this paper
• Changes of HbA1c variability after the switch to a longer‐acting insulin analog in people with type 1 diabetes

  2022cites this paper
• Pathophysiology and management of hypoglycemia in diabetes

  2022cites this paper
• Predictors of change in hypoglycemia unawareness among patients with type 1 diabetes

  2022cites this paper
• Pregnancy outcomes in women with type 1 diabetes using insulin degludec: response to Kamran et al

  2022cites this paper
• Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.

  2022cites this paper
• Factors associated with clinically significant hypoglycemia in patients with type 1 diabetes using sensor-augmented pump therapy with predictive low-glucose management: A multicentric study on iberoamerica.

  2021cites this paper
• Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

  2021cites this paper
• Nocturnal Hypoglycaemia in Patients with Diabetes Mellitus: Database Analysis of a Cohort Using Telemedicine Support for Self-Monitoring of Blood Glucose over a 10-Year-Long Period

  2021cites this paper
• Diabetes mellitus Typ 1 – Update

  2021cites this paper
• One Hundred Years of Insulin

  2021cites this paper
• Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

  2021cites this paper
• Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial

  2021cites this paper
• The Evolution of Insulin Administration in Type 1 Diabetes

  2021cites this paper
• The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2021cites this paper
• Clinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes

  2021cites this paper
• Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia

  2021cites this paper
• Series: Cardiovascular outcome trials for diabetes drugs Degludec and DEVOTE

  2021cites this paper
• Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update

  2021cites this paper
• Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes

  2021cites this paper
• A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec

  2021cites this paper
• The ongoing evolution of basal insulin therapy over 100 years and its promise for the future

  2021cites this paper
• Erythrocyte-Membrane-Enveloped Biomineralized Metal-Organic Framework Nanoparticles Enable Intravenous Glucose-Responsive Insulin Delivery.

  2021cites this paper
• Ultralong Analogue Insulin Degludec in Type 1 Diabetes : Reduction of Hypoglycemic Events

  2021cites this paper
• Clinical approaches to treat impaired awareness of hypoglycaemia

  2021cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study

  2021cites this paper
• Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?

  2021cites this paper
• Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

  2021cites this paper
• Recent Advances in Insulin Therapy

  2020cites this paper
• Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study

  2020cites this paper
• Pharmacological therapies to address obesity in type 1 diabetes.

  2020cites this paper
• Type 1 Diabetes in Youth and Technology-Based Advances in Management.

  2020cites this paper
• Are newer insulin analogues better for people with Type 1 diabetes?

  2020cites this paper
• The Evolution of Insulin and How it Informs Therapy and Treatment Choices

  2020cites this paper
• DEGLUDEC INSULIN IN TYPE 1 DIABETIC PATIENTS: 18 MONTHS OF OBSERVATION

  2020influential citation
• Aktuelle Therapien und Technologien in der Kinderdiabetologie

  2020cites this paper
• Low glucose suspend systems

  2020cites this paper
• [Diabetic patients, knowledge respectives complications and severity].

  2020cites this paper